Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

A phase II study of temozolomide therapy for poor-risk patients aged 60 years with acute myeloid leukemia: low levels of MGMT predict for response

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson M, Clark RE . Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1302–1311.

    Article  CAS  Google Scholar 

  2. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1312–1320.

    Article  CAS  Google Scholar 

  3. Gupta V, Chun K, Yi Q-L, Minden M, Schuh A, Wells R et al. Disease biology rather than age is the most important determinant of survival of AML patients 60 years treated with uniform intensive therapy. Cancer 2005; 103: 2082–2090.

    Article  Google Scholar 

  4. Leopold LH, Willemze R . The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature. Leuk Lymph 2002; 43: 1715–1727.

    Article  CAS  Google Scholar 

  5. Seiter K, Liu D, Loughran T, Siddiqui A, Baskind P, Ahmed T . Phase I study of temozolomide in relapsed/refractory acute leukemia. J Clin Oncol 2002; 20: 3249–3253.

    Article  CAS  Google Scholar 

  6. Graziani G, Faraoni I, Grohmann U, Bianchi R, Binaglia L, Margison GP et al. O6-alkylguanine-DNA alkyltransferase attenuates triazene-induced cytotoxicity and tumor cell immunogenicity in murine L1210 leukemia. Cancer Res 1995; 55: 6231–6236.

    CAS  Google Scholar 

  7. Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997–1003.

    Article  CAS  Google Scholar 

  8. D’Atri S, Piccioni D, Castellano A, Tuorto V, Franchi A, Lu K et al. Chemosensitivity to triazene compounds and O6-alkylguanine-DNA alkyltransferase levels: studies with blasts of leukemia patients. Ann Oncol 1995; 6: 389–393.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J M Brandwein.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brandwein, J., Yang, L., Schimmer, A. et al. A phase II study of temozolomide therapy for poor-risk patients aged 60 years with acute myeloid leukemia: low levels of MGMT predict for response. Leukemia 21, 821–824 (2007). https://doi.org/10.1038/sj.leu.2404545

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404545

This article is cited by

Search

Quick links